MLchartDataset catalogue

dabigatran

Term · Oncology and biomedicine · MLC-T-ONC-012891

A benzimidazole and direct thrombin inhibitor, with anticoagulant activity. Upon administration, dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.

Table 1. Record
IdentifierMLC-T-ONC-012891
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012891",
  "term": "dabigatran",
  "field": "Oncology and biomedicine",
  "definition": "A benzimidazole and direct thrombin inhibitor, with anticoagulant activity. Upon administration, dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dabigatran/"
}

Record 5,642 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.